These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 23143733)

  • 1. Positive urine cytology and carcinoma in situ prior to second transurethral resection of the bladder correlate with positive second resection histology and the need for subsequent cystectomy.
    Lodde M; Mayr R; Martini T; Comploj E; Palermo S; Trenti E; Hanspeter E; Fritsche HM; Mian C; Pycha A
    World J Urol; 2012 Dec; 30(6):841-6. PubMed ID: 23143733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic accuracy of preoperative urinary smear test in patients with bladder urothelial carcinoma in a high-volume center.
    Restrepo-Gonzalez JA; Garcia-Perdomo HA; Varela R
    Arch Esp Urol; 2014 Apr; 67(3):243-8. PubMed ID: 24840589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bladder preservation or initial cystectomy in T1G3 bladder cancer: which parameters help in therapeutic decision-making?].
    Denzinger S; Burger M; Fritsche HM; Ganzer R; Blana A; Wieland WF; Otto W
    Aktuelle Urol; 2008 Jan; 39(1):58-61; discussion 62-3. PubMed ID: 18228189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Grading and staging of bladder carcinoma in transurethral resection specimens. Correlation with 105 matched cystectomy specimens.
    Cheng L; Neumann RM; Weaver AL; Cheville JC; Leibovich BC; Ramnani DM; Scherer BG; Nehra A; Zincke H; Bostwick DG
    Am J Clin Pathol; 2000 Feb; 113(2):275-9. PubMed ID: 10664630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative predictive factors of carcinoma in situ in the normal-appearing mucosa in patients who underwent an initial transurethral resection for non-muscle-invasive bladder cancer under white light cystoscopy.
    Iinuma K; Yuhara K; Kotaka H; Ozawa K; Kato D; Takai M; Nakane K; Mizutani K; Tsuchiya T; Koie T
    Cancer Rep (Hoboken); 2021 Apr; 4(2):e1321. PubMed ID: 33174397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients?
    Soria F; D'Andrea D; Moschini M; Giordano A; Mazzoli S; Pizzuto G; Hurle R; Colombo R; Briganti A; Altieri V; Shariat SF; Gontero P
    Urol Oncol; 2020 Mar; 38(3):77.e1-77.e7. PubMed ID: 31526650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Narrow-band imaging (NBI) and white light (WLI) transurethral resection of the bladder in the treatment of non-muscle-invasive bladder cancer.
    Montanari E; de la Rosette J; Longo F; Del Nero A; Laguna P
    Arch Ital Urol Androl; 2012 Dec; 84(4):179-83. PubMed ID: 23427740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy.
    De Berardinis E; Busetto GM; Antonini G; Giovannone R; Gentile V
    Int Urol Nephrol; 2011 Dec; 43(4):1047-57. PubMed ID: 21442469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The significance of urine cytology three consecutive days after transurethral resection as a predictor of superficial bladder cancer recurrence].
    Yumura Y; Takase K; Kato Y; Hamano A; Mikata K; Ogo Y; Noguchi S; Satomi Y
    Hinyokika Kiyo; 2004 Mar; 50(3):171-6. PubMed ID: 15148768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes in patients with pathological carcinoma in situ only disease at radical cystectomy.
    Hassan JM; Cookson MS; Smith JA; Johnson DL; Chang SS
    J Urol; 2004 Sep; 172(3):882-4. PubMed ID: 15310989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
    Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of diagnostic gain with hexaminolevulinate (HAL) in the setting of newly diagnosed non-muscle-invasive bladder cancer with positive results on urine cytology.
    Neuzillet Y; Methorst C; Schneider M; Lebret T; Rouanne M; Radulescu C; Molinie V; Dreyfus JF; Pelcat V; Botto H
    Urol Oncol; 2014 Nov; 32(8):1135-40. PubMed ID: 25023786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens.
    Kunju LP; You L; Zhang Y; Daignault S; Montie JE; Lee CT
    J Urol; 2008 Nov; 180(5):1928-32; discussion 1932. PubMed ID: 18801529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy of Transurethral Resection of the Bladder in Detecting Variant Histology of Bladder Cancer Compared with Radical Cystectomy.
    Lonati C; Baumeister P; Ornaghi PI; Di Trapani E; De Cobelli O; Rink M; Karnes RJ; Poyet C; Simone G; Afferi L; Necchi A; Briganti A; Montorsi F; Krajewski W; Antonelli A; Cerruto MA; Zamboni S; Simeone C; Mordasini L; Mattei A; Moschini M;
    Eur Urol Focus; 2022 Mar; 8(2):457-464. PubMed ID: 33867307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Accuracy of Hexaminolevulinate in a Cohort of Patients Undergoing Radical Cystectomy.
    Pagliarulo V; Alba S; Gallone MF; Di Stasi S; Cormio L; Petitti T; Buscarini M; Minafra P; Carrieri G
    J Endourol; 2017 Apr; 31(4):405-411. PubMed ID: 28145751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
    Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
    Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological upstaging detected in radical cystectomy procedures is associated with a significantly worse tumour-specific survival rate for patients with clinical T1 urothelial carcinoma of the urinary bladder.
    May M; Bastian PJ; Brookman-May S; Burger M; Bolenz C; Trojan L; Michel MS; Herrmann E; Wülfing C; Tiemann A; Müller SC; Ellinger J; Buchner A; Stief CG; Tilki D; Wieland WF; Gilfrich C; Höfner T; Hohenfellner M; Haferkamp A; Roigas J; Zacharias M; Gunia S; Fritsche HM
    Scand J Urol Nephrol; 2011 Sep; 45(4):251-7. PubMed ID: 21388337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.
    May M; Helke C; Nitzke T; Vogler H; Hoschke B
    Urol Int; 2004; 72(2):103-11. PubMed ID: 14963349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of high-risk non-muscle invasive bladder cancer.
    Brausi M; Olaru V
    Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.